Clinical Trial News | Page 5 of 8 | www.PharmaNewsDaily.com

Home » Archives by category » Clinical Trial News (Page 5)

Janssen depression medication esketamine nasal spray yields mixed results in phase 3 trial

September 23, 2018 No Comment

Janssen Pharmaceutical Companies of Johnson & Johnson depression medication esketamine nasal spray did not meet expectations in a phase 3 trial in patients with treatment-resistant depression. The late-stage randomized trial evaluated two fixed doses of esketamine – 56 mg and 84 mg along with an oral antidepressant in comparison to placebo plus oral antidepressant. Janssen […]

Oncternal begins phase 1b trial of breast cancer drug cirmtuzumab and paclitaxel combo

September 13, 2018 No Comment

US oncology company Oncternal Therapeutics said that the first patient enrolled in a phase 1b trial of its investigational breast cancer drug cirmtuzumab in combination with paclitaxel, a standard-of-care chemotherapy drug, has been dosed. The phase 1b trial is evaluating the anti-ROR1 monoclonal antibody cirmtuzumab combination with paclitaxel, in breast cancer patients who are negative […]

Humira biosimilar Cyltezo meets objective in phase 3 plaque psoriasis trial

September 13, 2018 No Comment

German pharma company Boehringer Ingelheim said that Cyltezo, a biosimilar to AbbVie psoriasis drug Humira, achieved clinical equivalence to the reference product in a phase 3 trial in patients with moderate-to-severe chronic plaque psoriasis. Cyltezo succeeded in the NCT 02850965 phase 3 trial by not showing any clinically meaningful differences in efficacy, safety and immunogenicity […]

Alkermes to evaluate ALKS 4230, pembrolizumab combo for solid tumors

September 11, 2018 No Comment

Irish biopharma company Alkermes said that it has expanded an ongoing phase 1 trial for its immuno oncology drug ALKS 4230 to assess its safety and anti-tumor activity in combination with Merck’s PD-1 inhibitor KEYTRUDA (pembrolizumab) in advanced solid tumors. According to Alkermes, ALKS 4230 is an engineered fusion protein which selectively binds and signals […]

PvP Biologics initiates Kuma062 human trials for celiac disease treatment

September 8, 2018 No Comment

PvP Biologics, a US pharma company, has initiated two phase 1 clinical trials for Kuma062 to evaluate the recombinant enzyme for celiac disease treatment. According to PvP Biologics, Kuma062 has been designed to be active under acidic stomach conditions and it specifically targets the parts of gluten that are behind the autoimmune reaction causing celiac […]

Compugen kickstarts phase 1 trial of cancer immunotherapy COM701

September 8, 2018 No Comment

Israeli pharma company Compugen has dosed the first patient in the phase 1 clinical trial which is evaluating the company’s cancer immunotherapy antibody COM701 in patients with advanced solid tumors. COM701 has been designed to target the PVRIG gene, which according to the Israeli pharma company is a novel immune checkpoint target it had identified […]

Phase 3 trial of Pexa-Vec for advanced liver cancer initiated in China

September 5, 2018 No Comment

South Korean biotech company SillaJen and Hong Kong-based Lee’s Pharmaceutical have enrolled the first patient in China for a phase 3 trial called PHOCUS which will evaluate the oncolytic immunotherapy Pexa-Vec for the treatment of advanced liver cancer. The PHOCUS trial will aim to have 600 patients on board across the world who did not […]

Kodiak enrolls patients for retinal disease drug KSI-301’s phase 1 trial

September 2, 2018 No Comment

Clinical trial news : Kodiak Sciences has completed enrollment of patients for a phase 1 safety and tolerability study to evaluate its retinal disease drug KSI-301. The California-based biotech company, which is focused on developing therapies for retinal diseases, said that the phase 1 trial for KSI-301 being held in the US is an open […]

Pfizer DMD drug domagrozumab fails in two clinical trials

August 31, 2018 No Comment

Pfizer DMD drug update : US pharma giant Pfizer will scrap a couple of ongoing clinical trials evaluating its humanized monoclonal antibody domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD) owing to negative results. The two trials of the Pfizer DMD drug are B5161002 – a phase 2 safety and efficacy study and […]

Novartis’ heart failure drug Entresto can be initiated early in hospitalized patients

August 26, 2018 No Comment

Swiss drugmaker Novartis unveiled new data on Entresto (sacubitril/valsartan) from a phase 4 study which confirms that the heart failure drug can be initiated early and safely across a broad range of heart failure patients with reduced ejection fraction (HFrEF), whose condition has been stabilized following hospitalization because of an acute heart failure episode. In […]